Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...
Nxera Pharma, which recently announced a number of job cuts in Cambridge, is putting on a brave face after suffering another ...
Numab to receive milestone payment. BoehringerIngelheimhasadvanceditsnovelmulti-specificantibodyforretinal diseasesresultingfromacollaborationwithNumabintopreclinicaldevelopment.
Galux has signed a research agreement with Boehringer Ingelheim to jointly explore the application of AI in precision protein ...
TipRanks on MSN
Nxera Pharma Regains Full Rights to Phase 2–Ready Schizophrenia Drug After Boehringer Ingelheim Opts Out
Sosei Group ( ($JP:4565) ) has provided an announcement. Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, ...
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer ...
Galux signed a research agreement with Boehringer Ingelheim to advance AI-driven precision protein design for next-generation ...
Even as obesity and diabetes heavyweights Eli Lilly and Novo Nordisk command headlines with their global manufacturing expansions, Boehringer Ingelheim is getting in on the action. Thursday, ...
Boehringer Ingelheim unveiled its evolved company brand this week, featuring the corporate claim: “Life forward.” The German pharma giant said the claim builds upon the company’s purpose of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback